September 3, 2019 · 9:00 pm
September Journal Club at the MRC CTU : “A patient-level pooled analysis of treatment shortening regimens for drug-susceptible pulmonary tuberculosis” – Imperial et al, Nature Medicine, November 2018
Three recent trials using 4-month, moxifloxacin containing regimens failed to show non-inferiority in comparison to 6 months of standard HRZE therapy in patients with smear positive, drug sensitive tuberculosis. In this paper Imperial and colleagues re-analysed data from 3,405 participants in these trials to identify populations eligible for 4-month treatment, define phenotypes that are hard to treat and evaluate the impact of adherence and dosing strategy on outcomes.
Please join us at the MRC CTU for a critical discussion of this paper and debate around whether it is time to reconsider the one-size fits all approach to TB management in favour of a stratified medicine approach.
Click here for full details of the event
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.